Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Eni will guarantee Dompé researchers access to its laboratories, support from the company's specialized staff, and use of its HPC5 supercomputer
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Advances Amgen's mission to serve patients with rare disease medicines
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
Balaxi Healthcare Ecuador S.A.S. has become a Wholly Owned Subsidiary of the company
The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the company
Post-acquisition of the balance 25% outstanding shares will result into Sun Pharma de México, S.A. de C.V. becoming a wholly-owned subsidiary of the company.
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
Subscribe To Our Newsletter & Stay Updated
